Date: 2011-01-05
Type of information: R&D agreement
Compound: transporting therapeutic proteins across the blood-brain barrier into the central nervous system
Company: to-BBB (The Netherlands) Synageva BioPharma (USA)
Therapeutic area: Rare diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 5th, 2011, Synageva BioPharma Corp and to-BBB technologies BV, a Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS). This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including lysosomal storage diseases.
Financial terms:
Latest news:
Is general: Yes